

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boill Healthcare Holdings Limited

保集健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1246)

DATE OF BOARD MEETING

References are made to the announcements (the “**Announcements**”) of the Company dated 30 June 2022, 19 July 2022 and 29 July 2022 in relation to, among other things, the unaudited annual results of the Group for the year ended 31 March 2022, the delay in publication of the 2022 Audited Annual Results and the postponement of the date of the Board meeting. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Board hereby announces that a meeting of the Board will be held on Monday, 8 August 2022 to consider and approve, among other matters, the 2022 Audited Annual Results and its publication, and to consider the payment of a final dividend, if any.

By order of the Board
Boill Healthcare Holdings Limited
Dai Dong Xing
Executive Director and Chairman

Hong Kong, 4 August 2022

As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Dai Dong Xing and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Mr. Chan Chi Keung, Billy, Mr. Xu Liang Wei and Mr. Wang Zhe.